Phase II and pharmacokinetic study of high-dose methotrexate in the treatment of advanced gynecologic malignancy. A Southwest Oncology Group trial

Robert D. Hilgers, David S Alberts, James C. Standefer, Betty E. Skipper, Nancy Jo Miles, James Borst

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Fifteen patients with advanced or recurrent gynecologic malignancy were treated with high-dose methotrexate (HDMTX) (1-8 g/M2) and citrovorum factor rescue (10-100 mg/ M2). One complete response (13%) and two improved responses occurred in eight patients (25%) with squamous cell carcinoma and one of seven patients (14%) with nonsquamous nontrophoblastic carcinoma had stable disease for 7 months. The median duration of survival in the squamous group was 9 months and in the nonsquamous groups 6.5 months. Mean serum MTX concentrations were proportional to the doses administered and typical two compartment plasma disappearance curves were seen. Adverse toxic reactions were not observed at serum MTX levels less than 7.8 × 10-7, M at 24 hr and 1 × 10-7 M at 48 hr post-MTX. Hematopoietic toxicity occurred most frequently with leukopenia observed in 19.5% of courses. Hepatic, renal, gastrointestinal, and dermatologic toxicities were observed infrequently. Drug-induced nephrotoxicity occurred in one patient and possibly related leukoencephalopathy occurred in another patient. On the basis of the relatively low response rate observed in this trial and the high expense of HDMTX therapy, the value of such therapy may be limited in advanced nontrophoblastic gynecologic cancer.

Original languageEnglish (US)
Pages (from-to)62-70
Number of pages9
JournalGynecologic Oncology
Volume18
Issue number1
DOIs
StatePublished - 1984

Fingerprint

Methotrexate
Pharmacokinetics
Neoplasms
Therapeutics
Leukoencephalopathies
Leucovorin
Poisons
Leukopenia
Serum
Squamous Cell Carcinoma
Carcinoma
Kidney
Survival
Liver
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Phase II and pharmacokinetic study of high-dose methotrexate in the treatment of advanced gynecologic malignancy. A Southwest Oncology Group trial. / Hilgers, Robert D.; Alberts, David S; Standefer, James C.; Skipper, Betty E.; Miles, Nancy Jo; Borst, James.

In: Gynecologic Oncology, Vol. 18, No. 1, 1984, p. 62-70.

Research output: Contribution to journalArticle

Hilgers, Robert D. ; Alberts, David S ; Standefer, James C. ; Skipper, Betty E. ; Miles, Nancy Jo ; Borst, James. / Phase II and pharmacokinetic study of high-dose methotrexate in the treatment of advanced gynecologic malignancy. A Southwest Oncology Group trial. In: Gynecologic Oncology. 1984 ; Vol. 18, No. 1. pp. 62-70.
@article{9f1a9c214e914a8b91157905bdc3c6e6,
title = "Phase II and pharmacokinetic study of high-dose methotrexate in the treatment of advanced gynecologic malignancy. A Southwest Oncology Group trial",
abstract = "Fifteen patients with advanced or recurrent gynecologic malignancy were treated with high-dose methotrexate (HDMTX) (1-8 g/M2) and citrovorum factor rescue (10-100 mg/ M2). One complete response (13{\%}) and two improved responses occurred in eight patients (25{\%}) with squamous cell carcinoma and one of seven patients (14{\%}) with nonsquamous nontrophoblastic carcinoma had stable disease for 7 months. The median duration of survival in the squamous group was 9 months and in the nonsquamous groups 6.5 months. Mean serum MTX concentrations were proportional to the doses administered and typical two compartment plasma disappearance curves were seen. Adverse toxic reactions were not observed at serum MTX levels less than 7.8 × 10-7, M at 24 hr and 1 × 10-7 M at 48 hr post-MTX. Hematopoietic toxicity occurred most frequently with leukopenia observed in 19.5{\%} of courses. Hepatic, renal, gastrointestinal, and dermatologic toxicities were observed infrequently. Drug-induced nephrotoxicity occurred in one patient and possibly related leukoencephalopathy occurred in another patient. On the basis of the relatively low response rate observed in this trial and the high expense of HDMTX therapy, the value of such therapy may be limited in advanced nontrophoblastic gynecologic cancer.",
author = "Hilgers, {Robert D.} and Alberts, {David S} and Standefer, {James C.} and Skipper, {Betty E.} and Miles, {Nancy Jo} and James Borst",
year = "1984",
doi = "10.1016/0090-8258(84)90007-6",
language = "English (US)",
volume = "18",
pages = "62--70",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Phase II and pharmacokinetic study of high-dose methotrexate in the treatment of advanced gynecologic malignancy. A Southwest Oncology Group trial

AU - Hilgers, Robert D.

AU - Alberts, David S

AU - Standefer, James C.

AU - Skipper, Betty E.

AU - Miles, Nancy Jo

AU - Borst, James

PY - 1984

Y1 - 1984

N2 - Fifteen patients with advanced or recurrent gynecologic malignancy were treated with high-dose methotrexate (HDMTX) (1-8 g/M2) and citrovorum factor rescue (10-100 mg/ M2). One complete response (13%) and two improved responses occurred in eight patients (25%) with squamous cell carcinoma and one of seven patients (14%) with nonsquamous nontrophoblastic carcinoma had stable disease for 7 months. The median duration of survival in the squamous group was 9 months and in the nonsquamous groups 6.5 months. Mean serum MTX concentrations were proportional to the doses administered and typical two compartment plasma disappearance curves were seen. Adverse toxic reactions were not observed at serum MTX levels less than 7.8 × 10-7, M at 24 hr and 1 × 10-7 M at 48 hr post-MTX. Hematopoietic toxicity occurred most frequently with leukopenia observed in 19.5% of courses. Hepatic, renal, gastrointestinal, and dermatologic toxicities were observed infrequently. Drug-induced nephrotoxicity occurred in one patient and possibly related leukoencephalopathy occurred in another patient. On the basis of the relatively low response rate observed in this trial and the high expense of HDMTX therapy, the value of such therapy may be limited in advanced nontrophoblastic gynecologic cancer.

AB - Fifteen patients with advanced or recurrent gynecologic malignancy were treated with high-dose methotrexate (HDMTX) (1-8 g/M2) and citrovorum factor rescue (10-100 mg/ M2). One complete response (13%) and two improved responses occurred in eight patients (25%) with squamous cell carcinoma and one of seven patients (14%) with nonsquamous nontrophoblastic carcinoma had stable disease for 7 months. The median duration of survival in the squamous group was 9 months and in the nonsquamous groups 6.5 months. Mean serum MTX concentrations were proportional to the doses administered and typical two compartment plasma disappearance curves were seen. Adverse toxic reactions were not observed at serum MTX levels less than 7.8 × 10-7, M at 24 hr and 1 × 10-7 M at 48 hr post-MTX. Hematopoietic toxicity occurred most frequently with leukopenia observed in 19.5% of courses. Hepatic, renal, gastrointestinal, and dermatologic toxicities were observed infrequently. Drug-induced nephrotoxicity occurred in one patient and possibly related leukoencephalopathy occurred in another patient. On the basis of the relatively low response rate observed in this trial and the high expense of HDMTX therapy, the value of such therapy may be limited in advanced nontrophoblastic gynecologic cancer.

UR - http://www.scopus.com/inward/record.url?scp=0021279887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021279887&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(84)90007-6

DO - 10.1016/0090-8258(84)90007-6

M3 - Article

C2 - 6609105

AN - SCOPUS:0021279887

VL - 18

SP - 62

EP - 70

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -